PRIMA clinical trial: Universal Radical Cure of P. vivax malaria
Reducing the risk of P. vivax after falciparum infections in co-endemic areas - a randomized controlled trial (PRIMA).
To compare the safety and efficacy of a high dose primaquine treatment in G6PD normal patients with P. falciparum to reduce the risk of subsequent P. vivax episodes to current standard practice for P. falciparum
- To assess the safety and efficacy of a 7-day course of high dose primaquine treatment regimen in preventing recurrent symptomatic P. vivax parasitaemia in G6PD normal patients following uncomplicated P. falciparum malaria.
- To assess the efficacy of a 7-day course of high dose primaquine treatment regimen in preventing recurrent symptomatic and asymptomatic P. vivax and parasitaemia
- To assess the relationship between Hb and G6PD activity over time
For more information visit the clinical trials website.